vimarsana.com

Latest Breaking News On - Rockwell med - Page 1 : vimarsana.com

H C Wainwright Reaffirms Their Buy Rating on Urogen Pharma (URGN)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGN – Research Report) today and set a price target of $2.

H C Wainwright Reaffirms Their Buy Rating on Verona Pharma (VRNA)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $3.

Analysts Opinions Are Mixed on These Healthcare Stocks: Rockwell Med (NASDAQ: RMTI), Biogen (NASDAQ: BIIB) and Prelude Therapeutics (NASDAQ: PRLD)

Markets Rockwell Med (RMTI) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $5.50. The company’s shares closed last Friday at $1.06, close to its 52-week low of $0.83. According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 13.2% and a 52.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as NeuroBo Pharmaceuticals, Bausch Health Companies, and Oramed Pharmaceuticals. Currently, the analyst consensus on Rockwell Med is a Moderate Buy with an average price target of $5.50. Biogen (BIIB) In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Biogen, with a price target of $244.00. The company’s shares closed last Friday at $262.63.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.